Abstract
Two hundred healthy adults seronegative for HBV markers received three 10 or 20 mcg injections of a vaccine formulated from HBsAg produced by a recombinant strain of the yeastSaccharomyces cerevisiae. The vaccine was administered intramuscularly at 0, 1, and 6 months in the deltoid region. The seroconversion rates, expressed in GMT/IU/1 were determined at 1, 2, 6, 7, 12, 24, 36 and 48 months following the initial injection. No severe or serious adverse reactions attributable to the HB vaccines were observed in any subject. The seroconversion rates following the 20 mcg dose of recombinant vaccine were always higher than those observed after the 10 mcg dose, but the differences were not statistically significant. Also the GMT values were lower after the 10 mcg dose of vaccine. Females showed a higher anti-HBs response than males; an age-dependent effect was observed in the anti-HBs response as regards both the percentage of responders and the antibody concentrations in the serum. No adverse reactions to the vaccine were observed. The rDNA vaccine did not induce a response to yeast-derived impurities and did not increase anti-yeast IgE antibody titres. The results of this study have shown that the Amgen rDNA vaccine is safe and clinically well tolerated, and that it provides protection against infection and disease. A vaccination dose of 20 mcg appears more advantageous for healthy adult subjects.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andrè F. (1990): Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine -Vaccine8(Supplement): 74–78.
Bitter G.,Egan K.,Burnette W.,Samal B.,Fieschko J.,Peterson D.,Downing M.,Wypych J. andLangley K. (1988): Hepatitis B vaccine produced in yeast -J. Med. Virol.25: 133–140.
Brown S.,Stanley C.,Howard C.,Zuckerman A. andSteward M. (1986): Antibody responses to recombinant and plasma-derived hepatitis B vaccines- Br. Med. J.292: 159–161.
Crovari P.,Gay A.,Bertorello C.,Furlano M. andDeFlora S. (1979): Epidemiological survey of hepatitis B virus infection in various groups of population -Boll. Ist. Sieroter. Milan.58: 25–40.
Dentico P.,Buongiorno R.,Baldi L.,Trotta F.,Pastore G. andSchiraldi O. (1987): Prevalenza ed incidenza dell'infezione da virus dell'epatite B (HBV) nelle unità di dialisi della Regione Puglia - Quad. Sclavo Diagn.23: 184–200.
Dentico P.,Zavoianni A.,Volpe A.,Buongiorno R.,Palma R.,Calasso A.,Pastore G. andSchiraldi O. (1990): Hepatitis B virus infection in hospital staff: epidemiology and persistence of vaccine-induced antibodies - Vaccine9: 438–442.
Giusti G.,Galanti B.,Gaeta G.,Ruggiero G. andPiccinino F. (1981): HBsAg carrier among blood donors in Italy - Hepato-Gastroenterology28: 96–98.
Goudeau A.,Denis F.,Mounier M.,Dubois F.,Klein J.,Godefroy A.,Ballet M. andMountij A. (1987): Postgrad. Med. J.63(Supplement 2): 125–128.
Hollinger F.,Troisi C. andPepe P.. (1986): Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast - J. Infect. Dis.153: 156–159.
Jilg W. andDeinhardt F. (1986): Results of immunisation with a recombinant yeast-derived hepatitis B vaccine - J. Infection13(Supplement A): 47–51.
Pasquini P.,han H.,Pileggi D.,Panà A.,Terzi I. andGuzzanti E. (1983): Prevalence of Hepatitis B markers in Italy - Am. J. Epidemiol.118: 699–709.
Scheiermann N.,Gesemann K.,Kreuzfelder E. andPaar D. (1987): Effects of a recombinant yeast-derived hepatitis B vaccine in healthy adults -Postgrad. Med. J.63(Supplement 2): 115–119.
Schiraldi O. andDentico P. (1989): Virus B Hepatitis and pregnancy. The fetus as a patient -Elsevier Science Publishers, Amsterdam 167–174.
Stephenne J. (1988): Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness - Vaccine6: 299–303.
Stroffolini T.,Pasquini P.,Mele A. andthe Collaborating Group for Vaccination Against Hepatitis B (1988): HBsAg carriers among pregnant women in Italy: Results from the screening during a vaccination campaign against hepatitis B - Public Health102: 329–333.
Utili R.,Galanti B. andDaVilla G. (1983): Hyperendemicity of viral hepatitis in the Neapolitan area: an epidemiological study - Boll. Ist. Sieroter. Milan.62: 145–152.
Author information
Authors and Affiliations
Additional information
Corresponding author.
Rights and permissions
About this article
Cite this article
Dentico, P., Buongiorno, R., Volpe, A. et al. Long term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. Eur J Epidemiol 8, 650–655 (1992). https://doi.org/10.1007/BF00145379
Issue Date:
DOI: https://doi.org/10.1007/BF00145379